Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 2—February 2021
Research Letter

Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam

Huynh Kim MaiComments to Author , Nguyen Bao Trieu, Trinh Hoang Long, Hoang Tien Thanh, Nguyen Dinh Luong, Le Xuan Huy, Lam Anh Nguyet, Dinh Nguyen Huy Man, Danielle E. Anderson, Tran Tan Thanh, Nguyen Van Vinh Chau, Guy Thwaites, Lin-Fa Wang, Le Van TanComments to Author , and Do Thai Hung
Author affiliations: Pasteur Institute, Nha Trang City, Vietnam (H.K. Mai, N.B. Trieu, T.H. Long, H.T. Thanh, N.D. Luong, L.X. Huy, D.T. Hung); Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (L.A. Nguyet, T.T. Thanh, G. Thwaites, L.V. Tan); Hospital for Tropical Diseases, Ho Chi Minh City (D.N.H. Man, N.V.V. Chau); Duke-NUS Medical School, Singapore (D.E. Anderson, L.-F. Wang); Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK (G. Thwaites); SingHealth Duke-NUS Global Health Institute, Singapore (L.-F. Wang)

Main Article

Figure

Antibody responses in 11 study participants, weeks 1–20 after PCR diagnosis of SARS-CoV-2 infection, Vietnam, 2020. A) Seroprevalence of SARS-CoV-2 among 11 COVID-19 patients. We followed testing protocols and the positive cutoff of 20% recommended in the Elecsys Anti–SARS-CoV-2 assay (Roche, https://diagnostics.roche.com) without any modification. Using these parameters, previous studies showed an excellent concordance between results from surrogate virus neutralization tests and conventional neutralizing antibody detection assays (3,4). Vertical bars denote 95% CIs. Graphs were created using GraphPad Prism version 8.0 (GraphPad software, https://www.graphpad.com). B) Kinetics of neutralizing antibodies measured by the surrogate neutralization assay (GenScript, https://www.genscript.com) with the 20% cutoff applied. We tested samples at 1:10 dilution as specified. Because of the limited availability of plasma samples, each sample was tested only once. RBD, receptor-binding domain; NAbs, neutralizing monoclonal antibodies; S, spike; N, nucleocapsid.

Figure. Antibody responses in 11 study participants, weeks 1–20 after PCR diagnosis of SARS-CoV-2 infection, Vietnam, 2020. A) Seroprevalence of SARS-CoV-2 among 11 COVID-19 patients. We followed testing protocols and the positive cutoff of 20% recommended in the Elecsys Anti–SARS-CoV-2 assay (Roche, https://diagnostics.roche.com) without any modification. Using these parameters, previous studies showed an excellent concordance between results from surrogate virus neutralization tests and conventional neutralizing antibody detection assays (3,4). Vertical bars denote 95% CIs. Graphs were created using GraphPad Prism version 8.0 (GraphPad software, https://www.graphpad.com). B) Kinetics of neutralizing antibodies measured by the surrogate neutralization assay (GenScript, https://www.genscript.com) with the 20% cutoff applied. We tested samples at 1:10 dilution as specified. Because of the limited availability of plasma samples, each sample was tested only once. RBD, receptor-binding domain; NAbs, neutralizing monoclonal antibodies; S, spike; N, nucleocapsid.

Main Article

References
  1. Zhu  N, Zhang  D, Wang  W, Li  X, Yang  B, Song  J, et al.; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:72733. DOIPubMedGoogle Scholar
  2. Chen  SY, Lee  YL, Lin  YC, Lee  NY, Liao  CH, Hung  YP, et al. Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan. Emerg Microbes Infect. 2020;9:215768. DOIPubMedGoogle Scholar
  3. Tan  CW, Chia  WN, Qin  X, Liu  P, Chen  MI, Tiu  C, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38:10738. DOIPubMedGoogle Scholar
  4. Perera  RAPM, Ko  R, Tsang  OTY, Hui  DSC, Kwan  MYM, Brackman  CJ, et al. Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat and hamster sera. J Clin Microbiol. 2020;JCM.02504-20. DOIPubMedGoogle Scholar
  5. Gudbjartsson  DF, Norddahl  GL, Melsted  P, Gunnarsdottir  K, Holm  H, Eythorsson  E, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383:172434. DOIPubMedGoogle Scholar
  6. Sun  B, Feng  Y, Mo  X, Zheng  P, Wang  Q, Li  P, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020;9:9408. DOIPubMedGoogle Scholar
  7. Folegatti  PM, Ewer  KJ, Aley  PK, Angus  B, Becker  S, Belij-Rammerstorfer  S, et al.; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:46778. DOIPubMedGoogle Scholar
  8. van Doremalen  N, Lambe  T, Spencer  A, Belij-Rammerstorfer  S, Purushotham  JN, Port  JR, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020;586:57882. DOIPubMedGoogle Scholar
  9. Deng  W, Bao  L, Liu  J, Xiao  C, Liu  J, Xue  J, et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science. 2020;369:81823. DOIPubMedGoogle Scholar

Main Article

Page created: November 13, 2020
Page updated: January 24, 2021
Page reviewed: January 24, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external